Begin Main Content Area

​Medication Death and Incident Review Team

The Pennsylvania Department of Drug and Alcohol Programs (DDAP) is pleased to announce the selection of the Medication Death and Incident Review (MDAIR) Team. The MDAIR team will focus on medication-related deaths and incidents involving medications approved by the United States Food and Drug Administration (FDA) for the treatment of opioid use disorder.  The team will work together to review medication-related deaths, communicate concerns, and develop best practices to prevent future medication-related deaths and incidents.  

This new team was created as Act 126 of 2020 updated the previous Methadone Death and Incident Review Law to include a review of death and incidents related to FDA-approved medications as a primary, secondary or contributing factor to the death or incident.  The composition of the team members can be found below.

Medication Death and Incident Review Team Composition

Act 148 Section 3. Establishment of Medication Death and Incident Review Team. (b) Composition - The team shall consist of the following individuals:    
Act 126 Members (Medication Death and Incident Review Team)
​(b)(1) The secretary or designee who will serve as the chairperson of the team    ​Secretary Jennifer Smith, Chair
​(2) The Director of the Bureau of Drug Alcohol Programs​Bureau of Admin Support/QI; discretionary for Licensing and County Program Oversight
(3) The following individuals appointed by the secretary:
​(i) A representative from an opioid-assisted treatment program;​Laura Murray, DO, DABAM
​(ii) A representative from a licensed drug and alcohol addiction treatment program that is not defined as an opioid assisted treatment program;    ​Amy Maurizio, MS, MBA, CAADC
​(iii) A representative from law enforcement recommended by a Statewide association representing members of law enforcement;​Chief David Steffen
​(iv) A representative from the medical community recommended by a Statewide association representing physicians;​Divya Venkat, MD
​(v) A district attorney recommended by a Statewide association representing district attorneys;    ​Matthew Fogal, JD
​(vi) A coroner or medical examiner recommended by a Statewide association representing county coroners and medical examiners;    ​Charles Kiessling, RN, BSN, PHRN, CEN
​(vii) A member of the public;​Zoe Soslow, MS
(viii) A patient or family advocate;Leslie Slagel, PhD, LPC-Family Advocate & Heather B. Moshier, MBA, CAADC, LSW (she/her)
​(ix) A representative from a recovery organization;​William Stauffer, LSW, CCS, CADC
​(x) An office-based agonist treatment provider who is assigned a waiver from the Drug Enforcement Administration, including a special identification number, commonly referred to as the 'X' DEA Number, to provide office-based prescribing of buprenorphine;​Perry Meadows, MD, JD, MBA, FAAFP
​(xi) A representative of the Department of Health who is affiliated with the Achieving Better Care by Monitoring All Prescriptions Program (ABC-MAP) known as the Achieving Better Care by Monitoring All Prescriptions Programs (ABC-MAP);    
​Carrie Thomas Goetz, PhD
​(xii) A toxicologist​Jeanette Trella, PharmD, BCPPS


If you have any questions, please contact RA-DAMDAIR@pa.gov.